We’re excited to highlight our grant to the #MakeSenseCampaign, part of the European Head and Neck Society, to help launch a new clinical trials resource on their website. Check it out here:
makesensecampaign.eu/en/cancer-in...
#HNSCC
#CloseInOnCancer
This season, we’re thankful for our colleagues, collaborators, and the patients and families impacted by cancer, who inspire our work every day.
Happy Thanksgiving from all of us at Merus.
#CloseInOnCancer
We’re excited to share this news about our collaboration with Halozyme. Read more about here:
ir.merus.nl/news-release...
#CloseInOnCancer
Today at #Target25, we presented interim clinical data from the phase 2 trial of petosemtamab in combination with standard of care FOLFOX/FOLFIRI in 1L and 2L metastatic colorectal cancer (mCRC) and petosemtamab monotherapy in 3L+ mCRC
#CloseInOnCancer
#ColorectalCancer
ir.merus.nl/news-release...
Interim data on petosemtamab presented today at #Targets25 demonstrate a robust response rate and a favorable, well-tolerated safety profile in metastatic colorectal cancer.
merus.nl/wp-content/u...
#CloseInOnCancer
#ColorectalCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action:
-Inhibition of EGFR ligand binding and downstream signaling
-Degradation of EGFR via LGR5 internalization
-Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ 3 distinct mechanisms of action
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
New talent. Same mission.
When we succeed, we give patients with cancer access to medicines that could change their lives.
We’re excited to welcome our new team members.
If you want to be part of something bigger, now is the time. Join us.
#CloseInOnCancer
On #WorldCancerResearchDay, we stand united with researchers around the world working towards new treatments and improved outcomes for patients living with cancer.
#CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct MOAs:
- Inhibition of EGFR ligand binding and downstream signaling
- Degradation of EGFR via LGR5 internalization
- Engagement of host immune cells via ADCP and enhanced ADCC
#CloseInOnCancer
Innovation drives progress – and meaningful progress comes when new therapies are both efficacious and safe. On #WorldPatientSafetyDay, and every day, we reaffirm our commitment to making patient safety a cornerstone in the development of new potential treatments for cancer.
#CloseInOnCancer
Petosemtamab, a bispecific antibody targeting EGFR x LGR5, is designed to employ three distinct mechanisms of action.
Keep following as we highlight each distinct mechanism.
#CloseInOnCancer
Petosemtamab is a novel and highly innovative bispecific antibody in development for Head and Neck cancer and Colorectal cancer, with a unique mechanism of action. www.mdpi.com/2072-6694/17...
Stay tuned to learn more about petosemtamab’s unique mechanism of action.
#CloseInOnCancer #HNSCC #CRC
Welcome Bharti, Matthew, and Deitmar! With multiple therapeutic candidates in the clinic, we’re building momentum toward our goal of becoming a leading oncology company. If you’re looking for a place where your work has real meaning, join us
careers.merus.nl
#CloseInOnCancer
We are proud to be developing petosemtamab, with its unique biology designed to have three distinct mechanisms of action: EGFR ligand blocking, EGFR receptor internalization and degradation in LGR5+ cells, and Fc-mediated activation of the innate immune system.
lnkd.in/eyGQrTpF
#CloseInOnCancer
We’re thrilled to welcome new members to the Merus team! Their expertise and passion will help us advance our novel approach to fighting cancer.
Now is an exciting time to be part of Merus.
Interested in joining us? Explore our opportunities.
#CloseInOnCancer
When the lab coats come off and the computers shut down, the thinking caps stay on. Meet the Merus Pub Quiz crew, a highly competitive group of colleagues participating in local trivia nights. It's just one of the ways we stay connected – and sharp – when we’re off the clock.
#CloseInOnCancer
Barbara is a member of the Clinical Operations team, where she drives clinical research forward by coordinating trial logistics, leading site management activities, and managing patient recruitment, all while prioritizing patient safety.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
We’re thrilled to welcome Brenda, Shelly, and Quimby to our team! Now is an exciting time to be part of Merus. We’re growing, we’re hiring, and we’re making an impact.
Interested in joining us? Explore our opportunities at careers.merus.nl.
#CloseInOnCancer #Hiring #LifeAtMerus #WelcomeToTheTeam
Behind our clinical trials is a group committed to science, strategy, and patient impact. Stefan and the Biomarker Operations team bring passion and precision to advancing Merus’ clinical programs. We’re grateful for their contributions every day.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
Merus’ Petosemtamab with Pembrolizumab Interim Data Continues to Demonstrate Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC
#CloseInOnCancer
ir.merus.nl/news-release...
Merus will hold a conference call and webcast on Thursday, May 22nd, at 5:30 p.m. ET to discuss updated interim clinical data on petosemtamab with pembrolizumab in 1L PD-L1+ r/m #HNSCC. The presentation and replay will be available in the Investors & Media section of our website.
#CloseInOnCancer
Yesterday, we celebrated Clinical Trial Awareness Day.
In the coming days, we’ll introduce you to Merus team members who embody our company-wide passion and sense of urgency to bring new treatments to patients with cancer.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
Today, we honor and thank the global community for helping to advance our clinical programs. Importantly, we are proud of the Merus team who demonstrate unwavering dedication to patients in need of new treatment options.
#ClinicalTrialsDay
#CTD2025
#CloseInOnCancer
